Administração de grelina como uma nova terapia para retardar o envelhecimento na Síndrome de Hutchinson-Gilford
Year: 2017
Type: dissertation
Abstract: Hutchinson-Gilford progeria syndrome (HGPS), a lethal genetic disorder, is characterized by premature aging. HGPS is most commonly caused by a de novo point mutation (C608G) within the LMNA gene, producing an abnormal lamin A protein termed progerin, whose accumulation leads to premature cellular senescence. HGPS children have short stature, low body weight, lipodystrophy and skin and bone abnormalities. The cardiovascular system is severely affected and, in most cases, children succumb to myocardial infarction or stroke at an average age of 14.6 years.Intriguingly, patients show an apparent absence of neurological symptoms, which has been attributed to the regulation of progerin expression in neural cells by microRNA 9. However, no further studies addressed this issue, and therefore, the actual impact of the disease on the brain remains elusive. In line with this, and given the role of hypothalamic dysfunction on whole-body aging, the first aim of this study was to investigate the effect of premature aging on the hypothalamus of a HGPS mouse model, the LmnaG609G/G609G mice. The results obtained suggest that protein levels of NPY and AgRP increased, while protein levels of POMC, decreased, in the hypothalamus of LmnaG609G/G609G mice along time. Interestingly, opposite trends in the gene expression of these neuropeptides were observed. The neuronal marker NeuN levels were also decreased suggesting that hypothalamic neuronal structure may be affected, however, no changes in the expression of SOX2, a neurogenesis marker, and BDND, a neurotrophic factor, were found. Our results also suggest impairments in the immunity of LmnaG609G/G609G mice given the decline in the expression and/or protein levels of inflammatory markers, namely GFAP, an astrocyte marker, Iba-1, a microglia marker, and IL-10, an anti-inflammatory cytokine. These are the first evidences pointing to hypothalamic dysfunction in this HGPS mouse model, with putative relevance for HGPS premature aging progression.Ghrelin is a 28 aminoacid acylated peptide that constitutes the endogenous ligand for growth hormone secretagogue receptor (GHS-R). Ghrelin and its receptor are widely expressed in the body and have been shown to have beneficial effects on several body functions and organs known to be affected in HGPS: stimulation of food intake and adiposity, cardiovascular protection, bone remodeling and cellular proliferation. Moreover, recent data from our group showed that ghrelin stimulates autophagy and promotes progerin clearance, rescues nuclear abnormalities, decreases DNA damage and enhances cell proliferative capacity, delaying cellular senescence in HGPS cells. Taking this into account, the second aim of this study was to investigate whether ghrelin administration delays premature aging phenotype of LmnaG609G/G609G mice. Ghrelin induced an increase, although modest, in the body weight of LmnaG609G/G609G mice, preventing the progressive loss of weight at later stages of the disease. It also increased blood glucose levels. Ghrelin-treated mice showed some alterations in locomotor activity and behavior, with decreased distanced travelled, mean velocity and time spent within arena center, suggesting that ghrelin may be potentiating anxiogenic behaviors. The size of most organs did not change with ghrelin. However, we observed that the weight of white adipose tissue was higher in ghrelin-treated LmnaG609G/G609G mice, and this increase was concomitant with an increase in white adipocyte size. We also observed that ghrelin increased the thickness of subcutaneous fat layer in the skin, which may be related with adipocyte proliferation and differentiation. Ghrelin-treated LmnaG609G/G609G mice showed an increase in the thickness of epidermis, enhanced hepatocyte proliferation and an increase in the splenic lymphatic tissue area, suggesting an effect on cell proliferation in these organs. An increase in muscle fibers size was also observed in LmnaG609G/G609G mice upon ghrelin treatment. Ghrelin modulated autophagy and cell proliferation, two mechanisms known to be compromised with aging. However, these effects were organ dependent. Surprisingly, we found that ghrelin decreased NPY and AgRP expression in the hypothalamus of LmnaG609G/G609G mice, but had the opposite effect on Lmna+/+ mice. It also attenuated the decrease in GFAP expression observed in these mice, and increased IL-10 expression. Altogether, these results show ghrelin beneficial effects on LmnaG609G/G609G body weight, hypoglycemia, and lipodystrophy and in the histological structure of several organs, ameliorating the premature aging phenotype of LmnaG609G/G609G mice.In summary, this study was the first to suggest hypothalamic alterations in a HGPS mouse model. Nevertheless, more studies are needed to better understand the role of hypothalamus on HGPS progression. In addition, this study supports ghrelin administration as a promising therapeutic strategy to thwart HGPS progression.
Institution: University of Coimbra
Language: Portuguese
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: G2655791421, G5569247326
OpenAlex ID: W7047418759
